Department of Ophthalmology, School of Medicine, Medical Sciences, Tehran University, Tehran, Iran.
Curr Eye Res. 2010 Jan;35(1):17-22. doi: 10.3109/02713680903395273.
To evaluate clinical outcome(s) and complication(s) of topical bevacizumab (avastin) in patients with impending recurrent pterygium.
This prospective clinical trial included 54 consecutive patients (54 eyes), who underwent pterygium surgery with bare sclera and mitomycin, and who were diagnosed with impending recurrent pterygium. Of the 54 patients, 26 received eye drops containing bevacizumab (5 mg/ml) twice a day and betamethasone four times daily for 1 week. In the other 28 patients, betamethasone alone was administered four times daily for 1 week. Follow-up times were 3-6 mos.
All patients in both groups failed, i.e., fibrovascular tissue (pterygia) eventually extended onto the cornea. However, in patients receiving topical bevacizumab, the mean progression of fibrovascular tissue extension during the first week, first month, and third month of follow-up was significantly less than that in the control group (p < 0.01). The mean duration for invasion of cornea in study group patients was significantly longer than that for control group patients (p < 0.01).
Short-term use of topical bevacizumab seems to be a safe and effective means for delaying recurrence of impending recurrent pterygia.
评估局部应用贝伐单抗（阿瓦斯汀）治疗即将复发的翼状胬肉患者的临床疗效和并发症。
本前瞻性临床试验纳入了 54 例（54 只眼）接受单纯巩膜暴露联合丝裂霉素 C 治疗且诊断为即将复发的翼状胬肉患者。其中 26 例患者术后每天滴注 2 次 5mg/ml 的贝伐单抗和每日 4 次倍他米松，共 1 周；另外 28 例患者仅接受每日 4 次倍他米松治疗，共 1 周。随访时间为 3-6 个月。
两组所有患者最终均失败，即纤维血管组织（翼状胬肉）最终延伸至角膜。然而，在接受局部贝伐单抗治疗的患者中，在随访的第 1 周、第 1 个月和第 3 个月，纤维血管组织延伸的平均进展速度明显低于对照组（p < 0.01）。研究组患者角膜浸润的平均持续时间明显长于对照组患者（p < 0.01）。
短期应用局部贝伐单抗似乎是一种安全有效的方法，可延缓即将复发的翼状胬肉的复发。
